Currently, Glutrasol IF is undergoing the Significant Scientific Acceptance (SSA) testing process. Upon completion of the SSA, it will be submitted for FDA approval and available to license. This entire process is scheduled to be completed in early 2018. Glutrasol VE is expected to be granted a US patent within the next 60 days at which time the SSA process would start for that product as well.
If you are interested in learning more, please contact us. Further resources are clickable below: